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Groningen, The Netherlands; †Department of Internal Medicine, Division of Nephrology, University Medical Centre
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Institute for Pharmacological Research, Bergamo, Italy; §Department of Epidemiology, University Medical Centre
Groningen, Groningen, The Netherlands; and |Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo,
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ABSTRACT
High sodium intake limits the antihypertensive and antiproteinuric effects of angiotensin-converting enzyme
(ACE) inhibitors in patients with CKD; however, whether dietary sodium also associates with progression
to ESRD is unknown.We conducted a post hoc analysis of the ﬁrst and second Ramipril Efﬁcacy in Nephrop-
athy trials to evaluate the association of sodium intake with proteinuria and progression to ESRD among
500 CKD patients without diabetes who were treated with ramipril (5 mg/d) and monitored with serial
24-hour urinary sodium and creatinine measurements. Urinary sodium/creatinine excretion deﬁned low
(,100 mEq/g), medium (100 to ,200 mEq/g), and high ($200 mEq/g) sodium intake. During a follow-up
of .4.25 years, 92 individuals (18.4%) developed ESRD. Among those with low, medium, and high sodium
intakes, the incidence of ESRD was 6.1 (95% conﬁdence interval [95% CI], 3.8–9.7), 7.9 (95% CI, 6.1–10.2),
and 18.2 (95% CI, 11.3–29.3) per 100 patient-years, respectively (P,0.001). Patients with high dietary
sodium exhibited a blunted antiproteinuric effect of ACE inhibition despite similar BP among groups. Each
100-mEq/g increase in urinary sodium/creatinine excretion associated with a 1.61-fold (95% CI, 1.15–2.24)
higher risk for ESRD; adjusting for baseline proteinuria attenuated this association to 1.38-fold (95% CI,
0.95–2.00). This association was independent from BP but was lost after adjusting for changes in proteinuria.
In summary, among patients with CKD but without diabetes, high dietary salt (.14 g daily) seems to blunt
the antiproteinuric effect of ACE inhibitor therapy and increase the risk for ESRD, independent of BP control.
J Am Soc Nephrol 23: 165–173, 2012. doi: 10.1681/ASN.2011040430
Increased urinary protein excretion is a major
determinant of progressive renal function loss in
participants with CKD. Studies in CKD patients
with and without diabetes showed that renopro-
tective treatments limit GFR decline and progres-
sion to ESRD to the extent they lower proteinuria,
independent of BP control.1–4 These ﬁndings imply
that urinary proteins should be reduced as far as
possible, ideally to ,1 g/d.5
Inhibitors of the renin-angiotensin system (RAS),
such as angiotensin-converting enzyme (ACE) inhib-
itors or angiotensin II receptor blockers (ARBs), are
the antihypertensivedrugs thatmost effectively reduce
urinary proteins and slow GFR decline in patients
withCKD.1–3,6 The efﬁcacy of treatment, however, is
heterogeneous and dependent on inborn7 and envi-
ronmental8–12 factors. Data in experimental diabe-
tes,13,14 adriamycin nephrosis,15 uninephrectomized
rats, or in Munich Wistar rats with spontaneously
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reduced nephron numbers16 uniformly show that expansion of
the sodiumpool, with glomerular hyperﬁltration and activation
of the renal RAS induced by enhanced sodium intake, all con-
tribute to blunt the BP and proteinuria lowering effect of RAS
inhibitors.17 Consistently, observational studies in humans
showed that increased dietary sodium intake increases protein-
uria and accelerates renal disease progression.18 However, no
study thus far has evaluated the associations between salt in-
take, proteinuria, and renal disease progression in patients
receiving RAS-inhibiting treatment. Hence, in this study, we eval-
uated the association of sodium intake with proteinuria and pro-
gression to ESRD in 500 patients with CKD retrieved from the
Ramipril Efﬁcacy in Nephropathy (REIN)1–3 and REIN-219 trials
who were receiving stable ramipril therapy. Our working hy-
pothesis was that the blunted antiproteinuric effect of RAS
inhibition therapy in patients with high salt intake might
translate into less effective protection against progression to
ESRD. This hypothesis was based on the experimental and
human evidence discussed above and arose before expectation
of outcome data in our patient population.
RESULTS
Baseline Characteristics
The 500 included participants had a mean of 5.462.8 urinary
sodium and creatinine measurements over a follow-up of
26.2615.6 months. Twenty-six patients (5.2%) had only one
measurement. Their baseline characteristics were similar to
those of patients with more measurements (data not shown).
Mean urinary sodium and sodium/creatinine excretion at
baseline were 177.6672.3 mEq/24 h and 139.0654.9 mEq/g,
respectively. On the basis of their average urinary sodium/
creatinine excretion during the observation period, 111, 336,
and 53 patients were categorized in the low sodium diet (LSD),
medium sodium diet (MSD), and high sodium diet (HSD)
groups, respectively (Table 1). Sodium intake was a relatively
ﬁxed trait because patient distribution to the three sodium
intake groups did not change signiﬁcantly when only baseline
urinary sodium/creatinine measurements were considered
(P=0.442). There were more men in the LSD group than in
the MSD and HSD groups and primary glomerular diseases
were more frequent in the LSD group than in the MSD group.
Body mass index, BP, and creatinine clearance at baseline were
similar among groups, whereas urinary protein/creatinine and
urea/creatinine excretion were signiﬁcantly lower in the LSD
and MSD groups than in the HSD group.
Sodium Diet Groups
Of the 92 patients (18.4%) who progressed to ESRD, 18
(16.2%) were in the LSD group, 57 (17.0%) were in the MSD
group, and 17 (32.1%) were in the HSD group (P,0.001;
Figure 1). The ESRD incidence rate per 100 patient-years
was 6.1 (95% conﬁdence interval [95% CI], 3.8– 9.7) in the









men, n (%) 100 (90.1) 251 (74.7) a 30 (56.6)a,b
age, yr, mean (SD) 52.0 (14.5) 51.2 (14.8) 56.2 (15.3)b
body surface area, m2, mean (SD) 1.81 (0.39) 1.82 (0.24) 1.78 (0.19)a
body mass index, kg/m2, mean (SD) 25.8 (3.8) 26.3 (4.7) 26.1 (5.1)
Renal disease, n (%)
glomerular 68 (61.8) 161 (47.9) a 26 (49.1)
interstitial, polycystic 3 (2.7) 13 (3.9) 3 (5.7)
other, unknown 40 (36.0) 162 (48.2)a 24 (45.3)
BP, mmHg, mean (SD)
systolic BP 142.4 (15.5) 144.5 (18.5) 146.2 (18.8)
diastolic BP 89.3 (10.1) 88.8 (11.0) 108.0 (10.7)
Renal parameters
creatinine clearance, ml/min, mean (SD) 43.8 (18.6) 43.6 (19.7) 40.1 (22.3)
urinary creatinine excretion, g/d, mean (SD) 1.4 (0.3) 1.3 (0.4) 1.1 (0.4)a,b
urinary protein excretion, g/d, median (IQR) 3.0 (2.7) 2.8 (2.4) 3.1 (2.4)
urinary protein/creatinine excretion, g/g, median (IQR) 2.0 (2.2) 2.1 (1.9) 2.6 (2.3)a,b
urinary urea excretion, mmol/d, mean (SD) 19.6 (11.2) 19.9 (7.6) 18.2 (7.3)
urinary urea/creatinine excretion, mmol/g, mean (SD) 14.4 (8.5) 15.3 (4.9) 17.4 (6.7)a
urinary sodium excretion, mEq/d, mean (SD) 121.5 (59.6) 185.2 (61.8)a 242.7 (82.7)a,b
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LSD group, 7.9 (95% CI, 6.1–10.2) in the MSD group, and
18.2 (95% CI, 11.3–29.3) in the HSD group. Patients in the
HSD group had a 3.3-fold (95% CI, 1.7–6.4) and 2.4-fold
(95% CI, 1.4–4.1) excess risk of progressing to ESRD com-
pared with patients in the LSD (P,0.001) or MSD (P=0.002)
groups, respectively. MSD patients compared with LSD pa-
tients had a nonsigniﬁcant 1.4-fold (95% CI, 0.8–2.4) excess
risk of progressing to ESRD. Data did not change appreciably
when the 26 patients with only one measurement of urinary
sodium/creatinine ratio were not considered in the analyses.
Urinary protein/creatinine excretion decreased after 3months
of treatment (Figure 2, left panel) by 31% (P,0.001), 25%
(P,0.001), and 20% (P=0.036) versus baseline in the LSD,
MSD, and HSD groups, respectively. Thus, the antiproteinu-
ric efﬁcacy of RAS inhibition was signiﬁcantly higher in LSD
patients compared with MSD (P=0.031) and HSD (P=0.034)
patients. Consistently, there was a signiﬁcant trend to less pro-
teinuria reduction for increasing salt intake (P=0.012). Af-
ter these initial changes, proteinuria declined further during
follow-up at a rate of 0.66% (95%CI, 0.00%–1.29%) permonth
(P=0.039). However, whereas proteinuria reduction was sus-
tained throughout the whole observation period in the LSD
and MSD groups, the antiproteinuric effect of RAS inhibition
waned over time and urinary protein excretion tended to in-
crease toward baseline values in the HSD group (Figure 2, left
panel). Unlike proteinuria, BP was similar in the three groups
at baseline (Figure 2, right panel), shortly after RAS initiation,
and on subsequent follow-up. Concomitant use of BP lower-
ing medications was similar among groups at baseline, whereas
on follow-up there were fewer patients taking diuretic therapy
in the LSD group than in the MSD or HSD groups (Table 2).
As observed in the 500 patients receiving ramipril therapy,
as well as in the cohort of 172 controls taking non–RAS in-
hibitor therapy, participants in the HSD group tended to have
more proteinuria at baseline and on follow-up than those in
the LSD and MSD groups, respectively. In controls, however,
there were no appreciable differences in follow-up changes in
proteinuria among salt intake groups. Again, BP was similar
among groups throughout the whole observation period (Fig-
ure 3, left and right panels, respectively).
Sodium Excretion as a Continuum
An 100 mEq/g increase in urinary sodium/creatinine ratio was
associatedwith a 1.61-fold (95%CI, 1.15–2.24) increase inESRD
occurrence. This association was independent of age, sex, un-
derlying renal disease, previous inclusion in the REINorREIN-2
trials, and baseline BP. The signiﬁcance of the association, how-
ever, was partially lost (hazard ratio [HR], 1.38; 95% CI, 0.95–
2.00) after adjusting for baseline proteinuria (Table 3).
In the multivariable model adjusted for age, sex, BP,
creatinine clearance, and concomitant antihypertensive treat-
ment at baseline and 24-hour urea excretion throughout the
whole study period, an 100mEq/g increase in urinary sodium/
creatinine ratiowas associatedwith1.67-fold (95%CI, 1.07–2.60)
excess risk of progression to ESRD (Table 3). Exploratory ana-
lyses showed that the association was independent of changes
in BP and antihypertensive co-medication on follow-up. Con-
versely, the signiﬁcance of the association (HR, 1.14; 95%
CI, 0.72–1.80) was fully lost after adjustment for baseline and
follow-up 24-hour urinary protein excretion (Table 3). Similar
ﬁndings were obtained when urinary sodium/creatinine excre-
tion was considered as a continuous variable (Figure 4). With
this approach, unadjusted analyses showed a strong association
between urinary sodium excretion and progression to ESRD
(model 1, Figure 4). The signiﬁcance of the association was
attenuated when analyses were adjusted for baseline protein-
uria (model 2) and was fully lost when adjustments included
changes in proteinuria during the follow-up (model 3).
Although similar ﬁndings were obtained when urinary
sodium excretion was not normalized for concomitant urinary
creatinine excretion (Table 3), the creatinine normalized model
provided a better ﬁt according to the Bayesian information cri-
teria (1012 versus 1016 for the non-normalized model, using
the same patients and measurements in both models).
Relationships between Sodium, Proteinuria, and ESRD
Urinary sodium/creatinine excretion was signiﬁcantly and
positively correlated with urinary protein/creatinine excre-
tion at baseline (R=0.134, P=0.013) and follow-up (R=0.182,
P,0.001), whereas no correlation was found with BP at base-
line (R=0.005, P=0.927) or during follow-up (R=0.031,
P=0.556). In turn, urinary protein/creatinine ratio at baseline
Figure 1. In 500 patients with proteinuric chronic nephropathies,
higher salt intake is associated with an increased risk of progression
to ESRD. Kaplan-Meier survival curves show time to progression to
ESRD in patients categorized in the LSD (dotted line), MSD (broken
line), or HSD (continuous line) groups according to their urinary/
creatinine ratio on follow-up.
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(HR, 1.30; 95%CI, 1.19–1.41) and follow-up (HR, 1.38; 95%CI,
1.30–1.47) predicted ESRD progression, independent of sex,
age, creatinine clearance, and BP.
DISCUSSION
This study has two key ﬁndings. First, in humans with non-
diabetic CKD who received ACE inhibitor therapy, high salt
intake is associated with increased risk of progression to ESRD.
Second, the excess risk associated with
increased salt exposure seems to be medi-
ated by blunted antiproteinuric effects of
ACE inhibitor therapy in this population.
Among the 500 study participants, those
who had a urinary sodium excretion.200
mEq/g of urinary creatinine had a 2.4- and
3.3-fold higher incidence of ESRD com-
pared with those with a urinary sodium/
creatinine excretion between 100 and 200
mEq/g or ,100 mEq/g, respectively. De-
spite a similar BP control, urinary proteins
decreased more in patients in the LSD and
MSD groups than in those in HSD group.
More importantly, in the HSD group, the
antiproteinuric effect of ramipril therapy waned over time and
urinary protein excretion tended to increase toward baseline
values. These ﬁndings are consistent with well established
evidence that the renoprotective effect of ACE inhibitors or
ARBs is largely explained by their effect of reducing urinary
proteins,1–4 an effect that is limited or even blunted by excess
sodium intake.8–12 Increased sodium exposure could also ex-
plain the “escape phenomenon” observed in previous studies
and why it was more frequent in participants who were not
taking concomitant diuretic therapy.20–23
Figure 2. In 500 patients with proteinuric chronic nephropathies taking ramipril therapy, higher salt intake is associated with more
proteinuria at baseline and less proteinuria reduction on follow-up, but does not appear to appreciably affect BP control. A and B,
respectively, show 24-hour urinary protein excretion and mean arterial pressure during follow-up in patients categorized in LSD (dotted
lines), MSD (broken lines), or HSD (continuous lines) groups according to their urinary sodium/creatinine ratio on follow-up. The two
upper panels show mean and SEM values, whereas the two lower panels show median changes from baseline.
Table 2. Concomitant antihypertensive treatments at baseline and
throughout follow-up in patient groups categorized as having been on an
LSD, MSD, or HSD
Baseline, n (%) Follow-up, n (%)
LSD MSD HSD LSD MSD HSD
a-Adrenergic agents 33 (29.7) 92 (27.4) 12 (22.6) 31 (27.9) 68 (20.2)a 7 (13.2)
b blockers 24 (21.6) 81 (24.1) 14 (26.4) 29 (26.1) 78 (23.2) 13 (24.5)
Calcium channel
antagonists
25 (22.5) 92 (27.4) 20 (37.7) 63 (56.8)a 184 (54.8)a 30 (56.6)a
Diuretics 40 (36.0) 132 (39.3) 23 (43.4) 35 (31.5) 154 (45.8)a,b 25 (47.2)b
Note that patients in the intensiﬁed BP control arm of the REIN-2 (which was achieved with felodipine)
were classiﬁed for this study as receiving calcium channel antagonists as concomitant treatment.
aP,0.05 versus baseline use in the same diet group.
bP,0.05 versus LSD in the same time period.
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On average, a 100-mEq increase in daily sodium excretion
per gram of creatinine (equivalent to an incremental intake
of 125 mEq of sodium or 7 g of salt) increased the risk of
ESRD by 61%. This excess risk was independent of age, sex,
underlying renal disease, creatinine clearance at inclusion,
protein intake, and BP control throughout the observation
period, but was no longer signiﬁcant when the analyses were
adjusted for 24-hour urinary protein excretion at inclusion
and on follow-up. Conversely, urinary sodium excretion was
positively correlated with baseline and follow-up proteinuria
Figure 3. In 172 patients with proteinuric chronic nephropathies taking non-RAS inhibitor therapy, higher salt intake tends to be
associated with more proteinuria, but does not appear to appreciably affect proteinuria reduction on follow-up or BP control. A and B,
respectively, show 24-hour urinary protein excretion and mean arterial pressure during follow-up in patients categorized in LSD (dotted
lines), MSD (broken lines), or HSD (continuous lines) groups according to their urinary sodium/creatinine ratio on follow-up. The two
upper panels show mean and SEM values, whereas the two lower panels show median changes from baseline.
Table 3. Time-dependent Cox model, HRs per 100 mEq/d of urinary sodium excretion and per 100 mEq/g of urinary
sodium/creatinine excretion
Urinary Sodium Excretion Urinary Sodium/Creatinine Excretion
HR (95% CI) P Value HR (95% CI) P Value
Unadjusted 1.35 (0.96–1.89) 0.089 1.61 (1.15–2.24) 0.005
Univariable adjusted
age 1.35 (0.96–1.90) 0.082 1.60 (1.14–2.24) 0.006
sex 1.33 (0.95–1.88) 0.099 1.77 (1.26–2.50) 0.001
REIN/REIN 2 cohort 1.37 (0.97–1.93) 0.074 1.77 (1.28–2.54) 0.001
diagnosis 1.34 (0.95–1.88) 0.094 1.61 (1.15–2.25) 0.005
BP 1.35 (0.95–1.91) 0.096 1.69 (1.19–2.40) 0.003
proteinuria 1.11 (0.77–1.60) 0.592 1.38 (0.95–2.00) 0.086
Multivariable adjusteda
without proteinuria 1.67 (1.16–2.39) 0.006 1.67 (1.07–2.60) 0.025
including proteinuria 1.36 (0.89–2.06) 0.150 1.37 (0.84–2.22) 0.202
Adjusted for changes during follow-up (time-dependent)
BP 1.67 (1.16–2.42) 0.006 1.59 (1.01–2.50) 0.047
proteinuria 1.28 (0.86–1.92) 0.223 1.14 (0.72–1.80) 0.573
aThe multivariable model was adjusted for age, sex, mean arterial BP at baseline, antihypertensive co-medication at baseline, urinary urea excretion during follow-
up, and baseline creatinine clearance
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that, in turn, independently predicted the risk of ESRD pro-
gression. Although the numbers of events and patients were
too small to formally test the possibility of a signiﬁcant in-
teraction between urinary sodium excretion, proteinuria, and
risk of progression to ESRD, the above ﬁndings converge to
indicate that the association between salt intake and outcome
was largely mediated by the effects of salt exposure on pro-
teinuria. The ﬁnding that high sodium intake was associated
with more proteinuria already at inclusion was consistent with
previous data showing that daily sodium intake .200 mEq en-
hanced proteinuria in participants not receiving RAS inhibitor
therapy.18 Thus, our data suggest that participants with high salt
intake had more proteinuria at inclusion because of the associ-
ation of sodium overload with urinary proteins.8–11,24–28 This
interpretation is consistent with evidence that, among the 172
controls on non-RAS inhibitor therapy, proteinuria was also
more severe in those with high salt intake, while patient charac-
teristics and BP control were similar among salt intake groups.
The ﬁnding that BP control was independent of daily
sodium intake can be explained by the fact that antihyper-
tensive therapy was titrated to predeﬁned BP targets. Indeed,
participants with higher sodium intake more frequently
required combined treatment with a di-
uretic, which was the ﬁrst-line therapy in
both the REIN and REIN-2 studies.1–3,19
Addressing why the antiproteinuric and re-
noprotective effects of ACE inhibitor ther-
apy in participants with high sodium intake
were not restored by concomitant diuretic
therapy is beyond the purposes of this
study. A reasonable speculation is that so-
dium overload was not fully corrected by
diuretic therapy. To note, sodium overload
increases ACE activity in renal and vascular
tissues, which enhances vascular conversion
of AngI to AngII and blunts the effects of
ACE inhibition in rats and humans with
high sodium intake.29 Independent of BP
control, enhanced intrarenal ACE activity
has been associated with accelerated renal
damage in several experimental models of
chronic renal disease30 and might explain
at least part of the excess proteinuria and
renal risk associated with high sodium in-
take observed in this study.
Average sodiumintake approximated 10 g
per day, more than two-fold the intake rec-
ommended by current guidelines for re-
nal patients.31 This is of concern because
our data show that even a small increase in
salt intake is associated with an incremen-
tal risk of ESRD. A daily salt intake .14 g
(equivalent to.200 mEq/g creatinine) was
associated with an ESRD rate of 18.2% per
100 patient-years, compared with 7.9% in
participants with less salt intake. Previous studies consistently
showed the beneﬁts of a low-sodium diet on BP and protein-
uria, but provided no information on the harmful consequen-
ces of high salt intake on hard clinical end points.8–11 These
novel ﬁndings are relevant to health care providers because
prevention strategies aimed to avoid extreme excess in sodium
intake—even without dietary restrictions that might affect pa-
tient compliance32—would be extremely important to sub-
stantially limit the risk of renal disease progression in clinical
practice.
Monitoring Salt Intake
We categorized our patients according to three ranges of
sodium intake that were deﬁned on the basis of cut-off levels
similar to those used in previous studies.10,11,18,33 In contrast to
previous studies that used a single baseline measurement of
urinary salt excretion or the average of the measurements on
follow-up,34 in our time-dependent Cox model we used, for
the ﬁrst time in this clinical setting, a cumulative average of
sodium excretion. This is a gold-standard approach to model
the relationship between longitudinally measured covariates
and a given event35 that has been extensively applied in
Figure 4. In 500 patients with proteinuric chronic nephropathies taking ramipril therapy,
the association between salt intake and risk of progression to ESRD is lost when analyses
were adjusted for changes in proteinuria on follow-up. The three curves show the as-
sociation between urinary sodium/creatinine excretion on a continuous scale and ESRD
according to three Cox proportional hazards models: unadjusted (model 1), adjusted for
baseline proteinuria (model 2), and adjusted for baseline proteinuria and for changes in
proteinuria during follow-up (model 3).
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cardiovascular studies to assess the risk of events associated
with the consumption of certain foods or nutrients. This ap-
proach allowed us to reduce within-person data variability and
more reliably quantify long-term sodium exposure.36 In this
patient cohort, sodium intake was a relatively ﬁxed trait and
few patients appreciably changed their dietary sodium intake
during follow-up. Normalizing urinary sodium excretion to
concomitant creatinine excretion allowed us to account for
erroneous urine collections, but also resulted in an excess of
women and older patients in the HSD group that was likely
explained by the reduced urinary creatinine excretion in these
two populations. Because sodium and protein intake are often
correlated, we also adjusted the Cox model for urinary urea
excretion as a marker of dietary protein intake. Thus, the
association between urinary sodium excretion and ESRD
reﬂected a genuine predictive value of sodium intake unaffected
by a confounding effect of concomitant protein intake.
Strengths and Limitations
In addition to the use of gold-standard measures to monitor
salt intake, this study had two major strengths. First, our
analyses considered a hard end point, such as ESRD. Second,
the data were obtained from a large and homogenous pop-
ulation prospectively followed and treated according to stan-
dardized guidelines in the setting of controlled clinical studies.
This enhanced the clinical relevance of the study ﬁndings and
limited the confounding effect of random ﬂuctuations due
to heterogeneous patient characteristics and treatments. This
enhanced the reliability of the analysis and the robustness of
the ﬁndings, despite the relatively small number of patients
and events. The ﬁndings were further strengthened by evi-
dence that a similar association between sodium exposure and
outcomes was observed when urinary sodium excretion was
considered as a categorical or a continuous variable. More-
over, the ﬁnding that average sodium excretion in our study
populationwas similar to that reported in other observational
studies in renal patients37 or in general population samples38
enhanced the generalizability of the results. The major limi-
tation of this study is that this was a post hoc analysis of trials
originally designed for other purposes. Because of the obser-
vational nature of our study, a direct causal relationship be-
tween higher salt intake and worse outcome while taking ACE
inhibitor therapy cannot be deﬁnitely proven. Such an as-
sociation, however, was not appreciable in controls taking
non-RAS inhibitor therapy. Independent of the above, the
pathogenic role of excess sodium exposure could be deﬁnitely
addressed by intervention trials prospectively testing the as-
sociation of diets with different salt intake on renal disease
progression.
Our present observational analysis suggests that in CKD
patients receivingACE inhibitor therapy, high sodium intake is
associated with accelerated progression to ESRD, mediated by
increased proteinuria but independent of underlying renal
disease, BP control, and urea excretion, taken as a marker of
dietary protein intake. Avoiding excess sodium exposure may
be important to slow renal disease progression and limitations
in salt intake are expected to achieve major clinical beneﬁts in
this population that will largely offset the small inconveniences
ofminimal dietary restrictions.Optimal salt intake to optimize
renoprotection in the setting of amultimodal approach titrated
to urinary proteins and other determinants of renal disease




Of the 177 patients with proteinuric CKD included between 1992 and
1995 in the REIN trial1–3 and randomized to ramipril therapy and the
335 patients included between 1999 and 2003 in the REIN-2 trial all
treated with ramipril19 but not already included in the REIN trial, 500
(97.7%) had at least one measurement of 24-hour urinary sodium
excretion and were considered in this analysis. Both trials included
participants 18–70 years of age with CKD and persistent proteinuria
(urinary protein excretion $1 g/24 h for at least 3 months without
urinary tract infection or overt heart failure). Full study character-
istics and inclusion and exclusion criteria are detailed elsewhere.1–3,19
The primary outcome analyzed in both studies was the incidence of
doubling of serum creatinine or ESRD. Patients from both studies were
recommended a low-sodium diet and a daily protein intake of approx-
imately 0.8 g/kg. No change to diet was introduced during the obser-
vation period. Thus, all 500 patients included in this study fulﬁlled the
same selection criteria, had the same recommended diet, and were
receiving stable ACE inhibitor therapy with ramipril at the same daily
dose (5mg). The control groupwas composed of 172 patients from the
placebo arm of the REIN study who fulﬁlled the same selection criteria
and had been managed according to the same treatment and monitor-
ing guidelines, but had not received RAS inhibitor therapy. Patients in
the REIN and REIN-2 trials provided written informed consent to
participate, according to the Declaration of Helsinki guidelines. The
study protocols were approved by the ethics committee and institu-
tional review board of each of the participating centers.
Measurements
The exposure of interest, daily sodium intake, was estimated by mea-
suring 24-hour urinary sodium excretion. To correct for body size
and possible collection errors, urinary sodium excretion was nor-
malized to urinary creatinine excretion by calculating the sodium/
creatinine ratio from24-hour urine samples (sodium/creatinine ratio,
mEq/g).39 Urinary urea and protein excretion were normalized to
urinary creatinine excretion, as well. BP was measured at randomi-
zation and every 3 months thereafter. Creatinine clearance, 24-hour
urinary protein, and sodium and urea excretion were measured at
randomization, at 3 and 6 months after randomization, and every
6 months thereafter. Baseline data were taken when all participants
had completed the 6-week wash-out period from previous ACE inhib-
itor therapy, that is, at randomization for patients from the REIN trial
and at the inclusion visit for those from the REIN-2 trial. Thus, all
baseline data were without ACE inhibition and all outcome data were
with ramipril (5 mg/d) therapy.
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Statistical Analyses
As described in previous similar studies,11,18 we identiﬁed patients
with a LSD, MSD, or HSD based on urinary sodium/creatinine ex-
cretion averaged throughout the study ,100 mEq/g, between 100
mEq/g and 200 mEq/g, and .200 mEq/g (these cut-off levels of
100 mEq/g and 200 mEq/g approximated 125 and 250 mEq/d, equiv-
alent to 7 and 14 g of salt/d, respectively). Consistency of sodium
intake was assessed using the Stuart–Maxwell test. Differences in
baseline characteristics were determined using the Wilcoxon rank-
sum test and Fisher’s exact test, as appropriate. Differences in ESRD
incidence rates were tested using the chi-squared test. Differences in
short-term changes in proteinuria (percentage values6,10) and BP
(absolute values) were testedwithWilcoxon rank-sum tests; subsequent
changes were analyzed using a joint modeling approach incorporating
survival outcomes40 to account for survivor bias. Antihypertensive co-
medication was described; Fisher’s exact test andMcNemar’s test were
performed for comparisons among groups and time periods, respec-
tively. Survival curves were drawn using the Kaplan–Meier method;
the log-rank test was used to assess differences in survival among
groups and Cox proportional hazards analysis was used to calculate
hazard rates. Nonlinearity was tested by plotting the Martingale
residuals.
To reduce within-person data variability and reliably quantify
individual sodium exposure, sodium intake was also modeled con-
tinuously using time-dependent Cox models, with cumulative av-
erage of urinary sodium/creatinine excretion as the independent
variable.35,41 The hazard ratio for ESRD was determined per 100
mEq/g increase in sodium/creatinine ratio. Potential confounders
included in the Cox models were sex, age, baseline mean arterial
BP, use of antihypertensive co-medication at baseline, 24-hour uri-
nary urea excretion during follow-up, creatinine clearance at base-
line, and log-transformed 24-hour proteinuria at baseline. For
exploratory purposes, we adjusted for changes in mean BP and anti-
hypertensive co-medication during follow-up, and log-transformed
24-hour proteinuria during follow-up in separate Cox models. Cor-
relations between urinary sodium excretion and proteinuria or BP at
baseline and during follow-up were analyzed using linear regression;
at least twomeasurements per patient were required. Urinary sodium
and urea excretion at the last visit were not considered to avoid an
undesirable adjustment for sequelae,35 related to an anorectic de-
crease in nutritional intake just before the start of dialysis in patients
progressing to ESRD.42 All analyses were also performed using non-
normalized sodium excretion as an independent variable and the
two sodium metrics were compared through Bayesian information
criteria.43
All statistical analyses were performed using R software (version
2.5.1). All data are presented as mean 6 SD unless indicated other-
wise. P,0.05 was considered to be statistically signiﬁcant.
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